首页 > 市场调查报告书 > 製药

生物製剂分子标靶治疗学

市场调查报告书

商品编码

1733556

多特异性抗体的全球市场:药物销售额，用量，价格，临床试验趋势(2030年)

Global Multispecific Antibodies Market, Drug Sales, Dosage, Price & Clinical Trials Insight 2030

出版日期: 2025年05月01日 | 出版商:

KuicK Research | 英文 1200 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录图表

全球多特异性抗体市场、药品销售、剂量、价格、临床试验趋势（2030 年）报告重点

2030 年全球多特异性抗体市场机会：超过 500 亿美元
2024 年全球多特异性抗体市场收入：超过 120 亿美元
已核准多特异性抗体数量：18 种
全球及区域趋势
已核准抗体的全球、区域、年度和季度销售额
已核准抗体剂量与定价洞察
按公司、国家、适应症和阶段划分的临床试验中所有抗体的综合趋势
临床试验中多特异性抗体数量：700 多种

本报告彙编了关于全球多特异性抗体的全面一手和二手研究成果多特异性抗体市场，涵盖18种已获批准的药物，并提供定价、剂量和销售数据的深入分析。此外，还包括市场规模、已上市药物的区域销售分析以及最新发展。为了确保对多特异性抗体定价和市场表现分析的准确性和可靠性，我们利用了广泛的资讯来源，包括公司报告、交易所备案文件、年度和季度报告以及官方新闻稿。

我们检查了超过10,000个网页链接，以获取有关700多种多特异性抗体的全面临床试验资讯。
我们分析了美国证券交易委员会（SEC）的文件、公司报告、声明和新闻稿，以获得年度、季度、全球和区域销售分析。
我们访问了开源和专有资源，以验证FDA指定的罕见疾病药物的适应症和优先治疗重点。
我们研究了多个药品专用网站、各种新闻和公司新闻稿，以收集详细的药品价格和剂量资讯。

多特异性抗体市场是全球生物製药行业最具活力、成长最快的领域之一，这得益于治疗领域的突破，以及其透过同时靶向多种途径治疗复杂疾病的能力日益得到认可。截至2025年5月，全球已核准18种多特异性抗体，全部为双特异性抗体。这个不断扩展的产品组合包括一些开创性药物，例如第一个核准的双特异性抗体Blincyto，以及第一个获准用于非癌症适应症的双特异性抗体Hemlibra。该治疗产品线的最新成员是再生元的Lynozyfic，该药物于2025年4月获得上市许可，用于治疗多发性骨髓瘤，展现了该领域的持续发展势头。

核准的多特异性抗体种类繁多，反映了该疗法对不同适应症和患者群体的灵活性。同时，总部位于中国的康方生物的卡多尼利单抗是唯一获准的可同时靶向两个免疫检查点的双特异性抗体，也是第一个在中国研发并获批的双特异性抗体。这种区域性研发差异凸显了该领域创新的全球性，成熟医药市场和新兴生技中心都积极参与其中。

监管环境仍在快速变化，预计不久的将来会有更多药物获批。 FDA 也正在评估奥卓奈克塔单抗和瑞博舍塔单抗的上市申请。奥卓奈克塔单抗已在欧盟获准用于治疗滤泡性淋巴瘤，瑞博舍塔单抗则获准用于治疗瀰漫性大B细胞淋巴瘤和多发性骨髓瘤。跨大西洋监管领域的这种进展反映出全球监管机构对多特异性抗体技术的接受度和信心日益增强。

预计市场表现将异常强劲，全球多特异性抗体市场在2024年的销售额将超过126亿美元，2025年第一季的销售额将超过34.6亿美元。美国是该市场收入的最大贡献者，凸显了该关键地区的市场成熟度和接受度。罗氏的成熟产品Hemlibra和Vabysmo占了超过一半的市场占有率，凸显了先发优势和有效的市场进入策略在这个竞争激烈的市场中的价值。

多特异性抗体的研发管线更是令人望而生畏，目前已有超过900种多特异性抗体处于不同的研发阶段。肿瘤学领域引领这条管线，既是因为多特异性抗体研发的传统优先性，也是因为癌症治疗领域有大量未满足的医疗需求。然而，产品线的多样性并不局限于肿瘤学，在自体免疫、发炎和神经系统疾病领域也发现了一些有前景的候选药物，这表明治疗领域正在不断拓宽，并有可能大幅拓展市场机会。

支持这项创新的主要产业参与者包括安进、阿斯特捷利康、基因泰克和再生元等大型製药公司，以及ABL Bio、和铂医药、信达生物、Merus和Zymeworks等新兴生物技术公司。成熟公司和新兴公司的结合创造了充满活力的竞争格局，确保了持续的创新和技术进步。

策略联盟持续对市场发展产生影响，例如勃林格殷格翰与Cue Biopharma于2025年4月合作开发双特异性候选药物CUE-501，该药物可透过病毒特异性记忆T细胞攻击致病B细胞。此次合作涉及1,200万美元的首付款和高达3.45亿美元的里程碑付款，显示各公司正在投入大量资金推进多特异性抗体技术，尤其是在现有疗法不足的自身免疫性疾病领域。

美国食品药物管理局（FDA）将于2025年4月授予ISB 2001快速通道资格，该资格是Ichnos Glenmark Innovation公司用于治疗復发或难治性多发性骨髓瘤的在研三特异性T细胞介入疗法，这反映了该监管机构对推进多特异性抗体技术以治疗重大未满足医疗需求的持续热情。由于这项持续的技术创新，全球多特异性抗体市场预计将快速成长，并成为製药业最重要的细分市场之一。

本报告提供全球多特异性抗体市场相关调查，提供市场概要，以及药物趋势，临床试验趋势，各地区趋势，及加入此市场的主要企业的竞争情形等资讯。

AbbVie
ABL Bio
Abzyme Therapeutics
Affimed Therapeutics
Akeso Biopharma
Alligator Bioscience
Amgen
Antibody Therapeutics
APITBIO
Astellas Pharma
AstraZeneca
Aptevo Therapeutics
BioAtla
Biocytogen Pharmaceuticals
Biosion
EpimAb Biotherapeutics
FutureGen Biopharmaceutical
Genentech
Genmab
Genor Biopharma
Gensun Biopharma
Harbour BioMed
IGM Biosciences
I-MAB Biopharma
ImmuneOnco Biopharma
ImmunoPrecise Antibodies
Innate Pharma
Innovent Biologics
Invenra
Johnson & Johnson
Kenjockety Biotechnology
LaNova Medicines Limited
Light Chain Bioscience
Linton Pharm
Lyvgen Biopharma
MacroGenics
Merck
Merus
ModeX Therapeutics (OPKO Health)
Molecular Partners
NovaRock Biotherapeutics
Numab
OPKO Health
Pfizer
Regeneron Pharmaceuticals
Revitope
Roche
Sanofi
Sichuan Baili Pharmaceutical
SystImmune
Virtuoso Therapeutics
Xencor
Y-Biologics
Zhejiang Shimai Pharmaceutical
Zymeworks

简介目录图表

Global Multispecific Antibodies Market, Drug Sales, Dosage, Price & Clinical Trials Insight 2030 Report Highlights:

Global Multispecific Antibodies Market Opportunity By 2030: > USD 50 Billion
Global Multispecific Antibodies Market Sales In 2024: > USD 12 Billion
Number Of Approved Multispecific Antibodies: 18
Global & Regional Trends Insight
Approved Antibodies Global, Regional, Annual & Quarterly Sales Insight
Approved Antibodies Dosage & Pricing Insight
Comprehensive Insight On All Antibodies In Clinical Trials By Company, Country, Indication & Phase
Number Of Multispecific Antibodies: In Clinical Trials: > 700

Research Methodology

At Kuick Research, we begin by outlining the foundation of our research methodology, which is driven by an integrated approach that combines multiple data dimensions. In our work, we ensure that the report captures market estimation, regional analysis, and a carefully constructed competitive landscape. We take pride in the detailed inclusion of key components such as the assessment of available information, clinical trial data, and the nuances of dosing and pricing. Every piece of data is purposefully gathered and validated to ensure that our findings are as robust as possible, reflecting the multifaceted nature of the market landscape.

This report on the global multispecific antibodies market is the result of comprehensive primary and secondary research, encompassing 18 approved drugs, alongside in-depth analysis of their pricing, dosing, and sales data. Market size, marketed drugs regional sales analysis and recent trends are also included in the report. To ensure the accuracy and reliability of our analysis on multispecific antibodies pricing and market performance, we leveraged an extensive array of sources, including company reports, exchange filings, annual and quarterly reports, and official press releases.

Over 10000 distinct web links were reviewed for comprehensive clinical trial information on more than 700 multispecific antibodies.
For annual, quarterly, global and regional sales analysis, SEC documents, company reports, declarations, press releases were analyzed.
Open source and proprietary sources were accessed to validate FDA designated orphan drug indications & priority status.
Multiple drug specific website and various news, company press releases were examined to gather detailed drug pricing and dosage information

Multispecific antibodies market globally has been one of the most energetic and fast growing sectors in the biopharmaceutical business as a result of therapeutic breakthroughs and growing acceptance of their ability to treat complicated pathologies by targeting multiple pathways simultaneously. As of May 2025, 18 multispecific antibodies have gained regulatory approval globally, all of which are bispecific constructs, a monumental milestone in the history of targeted therapeutics. This expanding portfolio boasts trailblazing drugs like Blincyto, the first bispecific antibody to gain approval, and Hemlibra, which was the first bispecific antibody to be approved for a non-cancer indication. The latest entrant to this therapeutic pipeline is Regeneron's Lynozyfic, which received marketing approval in April 2025 for the treatment of multiple myeloma, with evidence of ongoing momentum in the segment.

The range of approved multispecific antibodies mirrors the flexibility of this therapeutic modality across various disease indications and patient bases. Rybrevant is another key breakthrough as the first bispecific antibody for a solid tumor, whereas China based Akeso's Cadonilimab is especially noteworthy for being solely approved bispecific antibody intended to target two immune checkpoints at once and becoming the first China developed bispecific antibody to gain regulatory approval. This regional variation in development emphasizes the world nature of innovation in this sector, with input from both mature pharmaceutical markets and developing biotechnology centers.

The regulatory environment is still changing at a rapid pace, with further approvals expected in the near future. The FDA is also evaluating marketing applications for Odronextamab and Linvoseltamab, both of which have already received approval in the EU for follicular lymphoma and diffuse large B-cell lymphoma, and multiple myeloma, respectively. Such transatlantic regulatory advancements reflect the growing acceptability and trust in multispecific antibody technologies by global regulatory bodies.

Market performance has been extremely strong, with global multispecific antibodies market sales in 2024 amounting to over US$ 12.6 Billion, followed by first quarter 2025 sales of over US$ 3.46 Billion. The US is the largest contributor to these sales, highlighting the maturity and acceptance of the market in this prime geography. Roche's mature products, Hemlibra and Vabysmo, lead the market share, with over half of total sales, emphasizing the value of first mover benefit and effective market entry strategies in this competitive market.

The pipeline for development is an even more daunting picture, with more than 900 multispecific antibodies already in various stages of development. Oncology is leading this pipeline, both due to the traditional priority of multispecific antibody development and due to the large unmet medical needs in cancer treatment. However, pipeline diversity is not confined to oncology alone with promising candidates being identified in autoimmune and inflammatory diseases and neurological disorders as well, indicating an expanding therapeutic horizon that has the potential to dramatically expand market opportunities.

Major industry players behind this innovation are well established pharma giants like Amgen, AstraZeneca, Genentech, and Regeneron, as well as new biotech firms like ABL Bio, Harbour BioMed, Innovent Biologics, Merus, and Zymeworks. This combination of well established and new players provides a vibrant competitive landscape that ensures ongoing innovation and technological progress.

Strategic alliances continue to influence the development of the market, such as in the April 2025 alliance of Boehringer Ingelheim and Cue Biopharma for the development of CUE-501, a bispecific candidate that attacks pathogenic B cells via virus-specific memory T cells. The alliance, involving a US$ 12 Million upfront payment and possible milestone payments of up to US$ 345 Million, illustrates the high financial investment that companies are undertaking to drive multispecific antibody technologies, specifically in autoimmune indications where existing treatments are still inadequate.

Regulatory encouragement of innovation continues to be robust, with the FDA's April 2025 fast track designation of ISB 2001, an Ichnos Glenmark Innovation investigational trispecific T-cell engager for relapsed or refractory multiple myeloma, reflecting ongoing regulatory enthusiasm for moving multispecific antibody technologies forward that treat important unmet medical needs. As a result of these ongoing innovations, the global multispecific antibody market is expected to grow rapidly and is on track to become one of the most important segments within the pharmaceutical industry.

1. Introduction to Next Generation Multispecific Antibodies

2. Next Generation Multispecific Antibody Current Clinical Development & Future Commercialization Outlook

2.1 Current Market Overview
2.2 Future Commercialization Opportunity
2.3 Collaborations, License Agreements, Investments & Acquisitions
2.4 Next Generation Multispecific Antibody Proprietary Technologies By Company

3. Next Generation Multispecific Antibody Clinical Trends by Indication

3.1 Cancer
3.2 Hematological Disorders
3.3 Microbial Infections
3.4 Autoimmune & Inflammatory Disorders
3.5 Ocular Diseases

4. Next Generation Multispecific Antibody Clinical Development & Market Trends by Region

4.1 US
4.2 EU
4.3 China
4.4 UK
4.5 Japan
4.6 Australia
4.7 South Korea
4.8 Canada

5. Approved Multispecific Antibodies - Clinical Overview, Pricing & Dosage Insight

5.1 Overview
5.2 Clinical Overview, Pricing & Dosage Insight

6. Approved Multispecific Antibodies - Sales Insight (2020 - Q1'2025)

7. Global Multispecific Antibodies Clinical Trials Overview

8. Global Bispecific Antibodies Clinical Trials By Company, Indication & Phase

8.1 Research
8.2 Preclinical
8.3 Phase-I
8.4 Phase-I/II
8.5 Phase-II
8.6 Phase-II/III
8.7 Phase-III
8.8 Preregistration
8.9 Registered

9. Marketed Bispecific Antibodies Clinical Insight By Company, Country & Indication

10. Global Trispecific Antibodies Clinical Trials Insight By Company, Country, Indication & Phase

10.1 Research
10.2 Preclinical
10.3 Phase I
10.4 Phase I/II
10.5 Phase II/III

11. Tetraspecific Antibodies Clinical Trials Insight By Company, Country, Indication & Phase

11.1 Preclinical
11.2 Phase I
11.3 Phase I/II
11.4 Phase II

12. Competitive Landscape

12.1 AbbVie
12.2 ABL Bio
12.3 Abzyme Therapeutics
12.4 Affimed Therapeutics
12.5 Akeso Biopharma
12.6 Alligator Bioscience
12.7 Amgen
12.8 Antibody Therapeutics
12.9 APITBIO
12.10 Astellas Pharma
12.11 AstraZeneca
12.12 Aptevo Therapeutics
12.13 BioAtla
12.14 Biocytogen Pharmaceuticals
12.15 Biosion
12.16 EpimAb Biotherapeutics
12.17 FutureGen Biopharmaceutical
12.18 Genentech
12.19 Genmab
12.20 Genor Biopharma
12.21 Gensun Biopharma
12.22 Harbour BioMed
12.23 IGM Biosciences
12.24 I-MAB Biopharma
12.25 ImmuneOnco Biopharma
12.26 ImmunoPrecise Antibodies
12.27 Innate Pharma
12.28 Innovent Biologics
12.29 Invenra
12.30 Johnson & Johnson
12.31 Kenjockety Biotechnology
12.32 LaNova Medicines Limited
12.33 Light Chain Bioscience
12.34 Linton Pharm
12.35 Lyvgen Biopharma
12.36 MacroGenics
12.37 Merck
12.38 Merus
12.39 ModeX Therapeutics (OPKO Health)
12.40 Molecular Partners
12.41 NovaRock Biotherapeutics
12.42 Numab
12.43 OPKO Health
12.44 Pfizer
12.45 Regeneron Pharmaceuticals
12.46 Revitope
12.47 Roche
12.48 Sanofi
12.49 Sichuan Baili Pharmaceutical
12.50 SystImmune
12.51 Virtuoso Therapeutics
12.52 Xencor
12.53 Y-Biologics
12.54 Zhejiang Shimai Pharmaceutical
12.55 Zymeworks

简介目录图表

List of Figures

Figure 2-1: Global - Multispecific Antibodies Sales (US$ Million), 2020-2025
Figure 2-2: Global - Market Sales by Multispecific Antibodies (US$ Million), Q1'2025
Figure 2-3: Global -Market Sales by Multispecific Antibodies (%), Q1'2025
Figure 2-4: Global - Market Sales by Multispecific Antibodies (US$ Million), 2024
Figure 2-5: Global -Market Sales by Multispecific Antibodies (%),2024
Figure 2-6: Global - Multispecific Antibodies Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 2-7: US - Multispecific Antibodies Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 2-8: ROW - Multispecific Antibodies Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 2-9: Global - Multispecific Antibody Market Opportunity Assessment (US$ Billion), 2025 - 2030
Figure 2-10: Grabody I Platform - Mechanism of Action 1
Figure 2-11: Grabody I Platform - Mechanism of Action 2
Figure 2-12: Abz2 Bispecific Platform
Figure 2-13: Abz2 Bispecifics - Benefits
Figure 2-14: Neo-X-Prime Bispecific Mechanism
Figure 2-15: BiTE - Structure
Figure 2-16: BiTE Molecule
Figure 2-17: ADAPTIR Bispecific Structure
Figure 2-18: ADAPTIR-FLEX
Figure 2-19: BioAtla CABs - Features
Figure 2-20: BioAtla CABs - Benefits
Figure 2-21: FIT-Ig - Proprietary Bispecific Platform
Figure 2-22: 3-Step DuoBody Production Process
Figure 2-23: DuoHexaBody Molecules - Schematic
Figure 2-24: BEAT Platform - Multispecific Antibodies
Figure 2-25: IMBiologic Bispecific Antibodies - Strategy
Figure 2-26: IMBiologic Bispecific Antibodies - Mechanism of Action
Figure 2-27: ANKET(R) Platform - Innate Pharma
Figure 2-28: B-Body Bispecific Antibody - Structre
Figure 2-29: iTAb - Patented Structure
Figure 2-30: iTAb - Mechanism of Action
Figure 2-31: xLinkBsAb - Structure
Figure 2-32: Multiclonics - Distinctive Characteristics
Figure 2-33: Biclonics - Format
Figure 2-34: Merus - Triclonics Platform
Figure 2-35: STEALTH - ModeX Therapeutics
Figure 2-36: MSTAR - ModeX Therapeutics
Figure 2-37: MSTAR - Features
Figure 2-38: DARPin Platform - Molecular Partners
Figure 2-39: Novel HBICE
Figure 2-40: HBICE - Mechanism of Action 1
Figure 2-41: HBICE - Mechanism of Action 2
Figure 2-42: Numab Therapeutics - Technology
Figure 2-43: Phanes Therapeutics - PACbody Platform
Figure 2-44: Phanes Therapeutics - SPECpair Platform
Figure 2-45: Phanes Therapeutics - ATACCbody
Figure 2-46: Purple Biotech - Tribody Antibody Platform
Figure 2-47: PrecisionGATE Bispecific Antibody - Structure
Figure 2-48: Sanyou Super Trillion Common Light Chain Antibody Discovery Platform
Figure 2-49: GNC Antibodies - Sichuan Baili Pharmaceutical/SystImmune
Figure 2-50: Synimmune - Proprietary Bispecific Antibody Format
Figure 2-51: ALiCE - Characteristics
Figure 2-52: ALiCE - Schematic Diagram & Mechanism of Action
Figure 2-53: BiClone format
Figure 2-54: Zyngenia Technology Approach
Figure 3-1: Odronextamab (ELM-1) Phase I (NCT02290951) Study - Initiation & Completion Year
Figure 3-2: Odronextamab (ELM-1) Phase II (NCT03888105) Study - Initiation & Completion Year
Figure 3-3: Linvoseltamab (LINKER-MM1) Phase I/II (NCT03761108) Study - Initiation & Completion Year
Figure 3-4: PIT565 Phase I (NCT05397496) Study - Initiation & Completion Year
Figure 3-5: JNJ-79635322 Phase I (NCT05652335) Study - Initiation & Completion Year
Figure 3-6: GNC-038 Phase I/II (NCT05192486) Study - Initiation & Completion Year
Figure 3-7: GNC-038 Phase I/II (NCT05485753) Study - Initiation & Completion Year
Figure 3-8: IPH6501 Phase I/II (NCT06088654) Study - Initiation & Completion Year
Figure 3-9: AFM13 Phase I/II (NCT04074746) Study - Initiation & Completion Year
Figure 3-10: NM32-2668 Phase I (NCT06299163) Study - Initiation & Completion Year
Figure 3-11: GB263T Phase I/II (NCT05332574) Study - Initiation & Completion Year
Figure 3-12: GNC-039 Phase I (NCT04794972) Study - Initiation & Completion Year
Figure 3-13: Emicizumab (AHAEmi) Phase II (NCT05345197) Study - Initiation & Completion Year
Figure 3-14: Emicizumab Phase II/III (NCT06155955) Study - Initiation & Completion Year
Figure 3-15: Emicizumab (BCDI-XII) Phase I (NCT05500807) Study - Initiation & Completion Year
Figure 3-16: HMB-001 Phase I/II (NCT06211634) Study - Initiation & Completion Year
Figure 3-17: YBSW015 Early Phase I (NCT05369754) Study - Initiation & Completion Year
Figure 3-18: CLN-978 (CLN-978-SL-101) Phase I (NCT06613360) Study - Initiation & Completion Year
Figure 3-19: Vabysmo - Approval Year by Indication
Figure 3-20: Faricimab (MAGIC) Phase II (NCT05681884) Study - Initiation & Completion Year
Figure 3-21: Restoret (EYE103) - Tetravalent, Trispecific Antibody Binding Sites
Figure 3-22: Restoret (BRUNELLO) Phase II/III (NCT06571045) Study - Initiation & Completion Year
Figure 3-23: Restoret (BAROLO) Phase II/III (NCT06957080) Study - Initiation & Completion Year
Figure 4-1: US - Approved Multispecific Antibodies
Figure 4-2: EU - Approved Multispecific Antibodies
Figure 4-3: Japan - Approved Multispecific Antibodies
Figure 4-4: Chugai Pharmaceutical - Multispecific Antibody Clinical Pipeline
Figure 4-5: SAIL66 Phase I (NCT05735366) Study - Initiation & Completion Year
Figure 4-6: ONO-4685 (ONO-4685-05) Phase I (NCT06547528) Study - Initiation & Completion Year
Figure 4-7: ABL Bio - Bispecific Antibody Pipeline
Figure 4-8: ZW171 (ZWI-ZW171-101) Phase I (NCT06523803) Study - Initiation & Completion Year
Figure 5-1: Blincyto - Approval Year by Region
Figure 5-2: Blincyto - Patent Filing & Expiration Year
Figure 5-3: Blincyto - Treatment Regimen Cycles (Weeks)
Figure 5-4: Blincyto - Duration of Treatment Phase & Resting Phase in Induction & Consolidation Cycles for Treatment of MRD-Positive B-cell precursor (Days)
Figure 5-5: Blincyto - Recommended Number of Induction & Consolidation Treatment Cycle for Relapsed B-Cell Precursor ALL
Figure 5-6: Blincyto - Duration of Single Induction, Consolidation, Continued Cycle & Full Treatment for Relapsed B-Cell Precursor ALL (Weeks)
Figure 5-7: Hemlibra - Approval Years by Region
Figure 5-8: Hemlibra - Cost per Unit & Supply of 30 mg/mL Subcutaneous Injection of Different Volumes (US$), May'2025
Figure 5-9: Hemlibra - Cost per Unit & Supply of 150 mg/mL Subcutaneous Injection of Different Volumes (US$), May'2025
Figure 5-10: Hemlibra - Recommended Loading & Maintenance Dose for Treatment of Hemophilia (mg/kg/Week)
Figure 5-11: Rybrevant - Price per Unit & Supply of Intravenous Solution (US$), May'2025
Figure 5-12: Rybrevant - Recommended Dose per Cycle by Body Weight (mg)
Figure 5-13: Rybrevant - Dose Reduction in Patients with Weight less than 80 kg (mg)
Figure 5-14: Rybrevant - Dose Reduction in Patients with Weight more than 80 Kg (mg)
Figure 5-15: Vabysmo - First Approval Year by Region
Figure 5-16: Vabysmo - Price per Unit & Supply of Intravitreal Solution (US$), May'2025
Figure 5-17: Lunsumio - Approval Years by Region
Figure 5-18: US - Price per Unit & Supply of Lunsumio Intravenous Solution (US$), May'2025
Figure 5-19: EU - Price per Unit & Supply of Lunsumio Intravenous Solution (US$), May'2025
Figure 5-20: Tecvayli - Approval Years by Region
Figure 5-21: Tecvayli - Patent Acceptance & Expiration Years
Figure 5-22: US - Cost per Unit & Supply of Tecvayli Subcutaneous Solution (US$), May'2025
Figure 5-23: EU - Cost per Unit & Supply of Tecvayli Subcutaneous Solution (US$), May'2025
Figure 5-24: Columvi - Approval Year by Region
Figure 5-25: US - Price per Unit & Supply of Columvi Intravenous Solution (US$), May'2025
Figure 5-26: EU - Price per Unit & Supply of Columvi Intravenous Solution (US$), May'2025
Figure 5-27: Epkinly - Approval Year by Region
Figure 5-28: US - Cost per Unit & Supply of Epkinly Subcutaneous Solution (US$), May'2025
Figure 5-29: EU - Cost per Unit & Supply of Epkinly Subcutaneous Solution (US$), May'2025
Figure 5-30: Talvey - Approval Year by Region
Figure 5-31: Talquetamab - FDA & EMA Designation Year
Figure 5-32: Talvey - Patent Acceptance & Expiration Year
Figure 5-33: US - Price per Unit & Supply of Talvey Intravenous Solution (US$), May'2025
Figure 5-34: EU - Price per Unit & Supply of Talvey Intravenous Solution (US$), February'2024
Figure 5-35: Elrexfio - Approval Years by Region
Figure 5-36: Elranatamab - FDA & EMA Designation Year
Figure 5-37: US - Price per Unit & Supply of Elrexfio Subcutaneous Solution (US$), May'2025
Figure 5-38: Imdelltra - Approval Years by Region
Figure 5-39: Imdelltra - Price per Unit & Supply of Intravenous Powder (US$), May'2025
Figure 5-40: US - Price Per Unit & Supply Of Ziihera (US$), May'2025
Figure 5-41: Zenocutuzumab - Active Patents
Figure 6-1: Global - Annual Blincyto Sales (US$ Million), 2020-2025
Figure 6-2: Regional - Blincyto Sales (US$ Million), Q1'2025
Figure 6-3: Regional - Blincyto Sales Quarterly (%), Q1'2025
Figure 6-4: Blincyto - Sales By Region (US$ Million), 2024
Figure 6-5: Blincyto - Sales By Region (%), 2024
Figure 6-6: US - Blincyto Sales ((US$ Million), 2020-2025
Figure 6-7: US - Blincyto Sales Quarterly (US$ Million), 2024
Figure 6-8: ROW - Blincyto Sales (US$ Million), 2020-2025
Figure 6-9: ROW - Blincyto Sales Quarterly (US$ Million), 2024
Figure 6-10: Global - Annual Hemlibra Sales (US$ Million), 2020-2024
Figure 6-11: Regional - US v/s ROW Sales (US$ Million), Q1'2025
Figure 6-12: Global - Hemlibra Sales by Region (US$ Million), Q1'2025
Figure 6-13: Global - Hemlibra Sales by Region (%), Q1'2025
Figure 6-14: Regional - US v/s ROW Sales (US$ Million), 2024
Figure 6-15: Global - Hemlibra Sales by Region (US$ Million), 2024
Figure 6-16: Global - Hemlibra Sales by Region (%),'2024
Figure 6-17: Global - Hemlibra Sales Quarterly (US$ Million), 2024
Figure 6-18: US - Annual Hemlibra Sales (US$ Million), 2020-2025
Figure 6-19: US - Hemlibra Sales Quarterly (US$ Million), 2024
Figure 6-20: Europe - Annual Hemlibra Sales (US$ Million), 2020-2025
Figure 6-21: Europe - Hemlibra Sales Quarterly (US$ Million), 2024
Figure 6-22: Japan - Annual Hemlibra Sales (US$ Million), 2020-2025
Figure 6-23: Japan - Hemlibra Sales Quarterly (US$ Million), 2024
Figure 6-24: ROW - Hemlibra Sales (US$ Million), 2020-2025
Figure 6-25: ROW - Hemlibra Sales Quarterly (US$ Million), 2024
Figure 6-26: Global - Annual Vabysmo Sales (US$ Million), 2022-2025
Figure 6-27: Global - Vabysmo US v/s ROW Sales (US$ Million), Q1'2025
Figure 6-28: Global - Vabysmo Sales by Region (US$ Million), Q1'2025
Figure 6-29: Global - Vabysmo Annual Sales by Region (%), Q1'2025
Figure 6-30: Global - Vabysmo US v/s ROW Sales (US$ Million), 2024
Figure 6-31: Global - Vabysmo Sales by Region (US$ Million), 2024
Figure 6-32: Global - Vabysmo Annual Sales by Region (%), 2024
Figure 6-33: Global - Vabysmo Sales Quarterly (US$ Million), 2024
Figure 6-34: US - Vabysmo Sales (US$ Million), 2022-2025
Figure 6-35: US - Vabysmo Sales Quarterly (US$ Million), 2024
Figure 6-36: Europe - Vabysmo Sales (US$ Million), 2022-2025
Figure 6-37: Europe - Vabysmo Sales Quarterly (US$ Million), 2024
Figure 6-38: Japan - Vabysmo Sales (US$ Million), 2022-2025
Figure 6-39: Japan - Vabysmo Sales Quarterly (US$ Million), 2024
Figure 6-40: ROW - Vabysmo Sales (US$ Million), 2022-2025
Figure 6-41: ROW - Vabysmo Sales Quarterly (US$ Million), 2024
Figure 6-42: Global - Annual Lunsumio Sales (US$ Million), 2022-2025
Figure 6-43: Global - Lunsumio US v/s ROW Sales (US$ Million), Q1'2025
Figure 6-44: Global - Lunsumio Sales by Region (US$ Million), Q1'2025
Figure 6-45: Global - Lunsumio Annual Sales by Region (%), Q1'2025
Figure 6-46: Global - Lunsumio US v/s ROW Sales (US$ Million), 2024
Figure 6-47: Global - Lunsumio Sales by Region (US$ Million), 2024
Figure 6-48: Global - Lunsumio Annual Sales by Region (%), 2024
Figure 6-49: Global - Lunsumio Sales Quarterly (US$ Million), 2024
Figure 6-50: US - Lunsumio Sales (US$ Million), 2022-2025
Figure 6-51: US - Lunsumio Sales Quarterly (US$ Million), 2024
Figure 6-52: Europe - Lunsumio Sales (US$ Million), 2022-2025
Figure 6-53: Europe - Lunsumio Sales Quarterly (US$ Million), 2024
Figure 6-54: ROW - Lunsumio Sales (US$ Million), 2022-2025
Figure 6-55: ROW - Lunsumio Sales Quarterly (US$ Million), 2024
Figure 6-56: Global - Tecvayli Sales (US$ Million), 2022-2025
Figure 6-57: Regional - Tecvayli Sales US$ Million), Q1'2025
Figure 6-58: Regional - Tecvayli Sales (%), Q1'2025
Figure 6-59: Global - Tecvayli Sales Quarterly (US$ Million), 2024
Figure 6-60: Regional - Tecvayli Sales (US$ Million), 2024
Figure 6-61: Regional - Tecvayli Sales (%), 2024
Figure 6-62: US - Tecvayli Sales (US$ Million), 2022-2025
Figure 6-63: US - Tecvayli Sales Quaterly (US$ Million), 2024
Figure 6-64: ROW - Tecvayli Sales (US$ Million), 2022-2025
Figure 6-65: ROW - Tecvayli Sales Quarterly (US$ Million), 2024
Figure 6-66: Global - Annual Columvi Sales (US$ Million), 2023-2025
Figure 6-67: Regional - US v/s ROW Sales (US$ Million), Q1'2025
Figure 6-68: Global - Columvi Sales by Region (US$ Million), Q1'2025
Figure 6-69: Global - Columvi Sales by Region (%), Q1'2025
Figure 6-70: Regional - US v/s ROW Sales (US$ Million), 2024
Figure 6-71: Global - Columvi Sales by Region (US$ Million), 2024
Figure 6-72: Global - Columvi Sales by Region (%),'2024
Figure 6-73: Global - Columvi Sales Quarterly (US$ Million), 2024
Figure 6-74: US - Annual Columvi Sales (US$ Million), 2023-2025
Figure 6-75: US - Columvi Sales Quarterly (US$ Million), 2024
Figure 6-76: Europe - Annual Columvi Sales (US$ Million), 2023-2025
Figure 6-77: Europe - Columvi Sales Quarterly (US$ Million), 2024
Figure 6-78: ROW - Columvi Sales (US$ Million), 2023-2025
Figure 6-79: ROW - Columvi Sales Quarterly (US$ Million), 2024
Figure 6-80: Global - Annual Epkinly Sales (US$ Million), 2023-2025
Figure 6-81: Global - Columvi Sales Quarterly Reported by AbbVie (US$ Million), 2024
Figure 6-82: US - Columvi Sales Quarterly Reported by AbbVie (US$ Million), 2024
Figure 6-83: ROW - Columvi Sales Quarterly Reported by AbbVie (US$ Million), 2024
Figure 6-84: Annual - Cadonilimab Sales (US$ Million), 2022-2024
Figure 6-85: Global - Annual Talvey Sales (US$ Million), 2025
Figure 6-86: Regional - Talvey Sales (US$ Million), Q1'2025
Figure 6-87: Regional - Talvey Sales Quarterly (%), Q1'2025
Figure 6-88: Global - Elrexfio Sales (US$ Million), 2023-2025
Figure 6-89: Global - Annual Elrexfio Sales (US$ Million), 2025
Figure 6-90: Regional - Elrexfio Sales (US$ Million), Q1'2025
Figure 6-91: Regional - Elrexfio Sales Quarterly (%), Q1'2025
Figure 6-92: US - Elrexfio Sales (US$ Million), 2023-2025
Figure 6-93: ROW - Elrexfio Sales (US$ Million), 2023-2025
Figure 6-94: Global - Imdelltra Sales (US$ Million), 2024-2025
Figure 6-95: Regional - Imdelltra Sales (US$ Million), Q1'2025
Figure 6-96: Regional - Imdelltra Sales Quarterly (%), Q1'2025
Figure 6-97: Global - Imdelltra Sales Quarterly (US$ Million), 2024
Figure 6-98: US - Imdelltra Sales (US$ Million), 2024-2025
Figure 6-99: US - Imdelltra Sales (US$ Million), 2024-2025
Figure 6-100: ROW - Imdelltra Sales (US$ Million), 2024-2025
Figure 6-101: Global - Ordspono Sales (US$ Million), 2022-2024
Figure 6-102: Global - Ordspono Sales Quarterly (US$ Million), 2024
Figure 6-103: Global - Ziihera Sales (US$ Million), 2024
Figure 7-1: Global - Multispecific Antibodies Clinical Trials by Phase (Numbers), 2025 till 2030
Figure 7-2: Global - Bispecific Antibodies Clinical Trials by Phase (Numbers), 2025 till 2030
Figure 7-3: Global - Tetraspecific Antibodies Clinical Trials By Phase (Number Of Antibodies), 2025 till 2030
Figure 7-4: Global - Trispecific Antibodies Clinical Trials by Phase, 2025 till 2030

List of Tables

Table 2-1: Estimated Total Cancer Cases, 2022 & 2040
Table 2-2: Multispecific Antibodies Under Regulatory Review
Table 3-1: Hematological Cancers - Approved Multispecific Antibodies
Table 3-2: Hematological Malignancies - Estimated Total Cancer Cases, 2022 & 2040
Table 3-3: Solid Cancers - Approved Multispecific Antibodies
Table 3-4: Solid Cancers - Estimated Total Cancer Cases, 2022 & 2040
Table 4-1: US - Multispecific Antibodies in Clinical Trials
Table 4-2: EU - Multispecific Antibodies in Clinical Trials
Table 4-3: UK - Multispecific Antibodies in Clinical Trials
Table 4-4: Japan - Multispecific Antibodies in Clinical Trials
Table 4-5: Australia - Multispecific Antibodies in Clinical Trials
Table 4-6: South Korea - Multispecific Antibodies in Clinical Trials
Table 4-7: Canada - Multispecific Antibodies in Clinical Trials
Table 5-1: Approved Multispecific Antibodies
Table 5-2: Blincyto - Active Patents
Table 5-3: Blincyto - Recommended Dosage & Schedule for the Treatment of MRD-positive B-cell Precursor ALL
Table 5-4: Blincyto - Recommended Dosage & Schedule for Treatment of Relapsed or Refractory B-cell Precursor ALL
Table 5-5: Blincyto - Recommended Dosage & Schedule for Treatment of Relapsed or Refractory B-cell Precursor ALL
Table 5-6: Rybrevant - Premedication
Table 5-7: Rybrevant - Dose Reductions for Adverse Reactions
Table 5-8: Rybrevant - Recommended Dosage Modifications for Adverse Reactions
Table 5-9: Lunsumio - Recommended Treatment Cycles
Table 5-10: Lunsumio - Recommended Premedications
Table 5-11: Lunsumio - Recommendations for Management of Cytokine Release Syndrome
Table 5-12: Tecvayli - Dosing Schedule
Table 5-13: Tecvayli - Recommended Dosage Modifications for Adverse Reactions
Table 5-14: Columvi - Dosing Schedule (21-Day Treatment Cycles)
Table 5-15: Columvi - Premedications to be Administered
Table 5-16: Columvi - Recommendations for Management of Cytokine Release Syndrome
Table 5-17: Columvi - Recommended Dosage Modification for Neurologic Toxicity (Including ICANS)
Table 5-18: Columvi - Recommended Dosage Modifications for Other Adverse Reactions
Table 5-19: Epkinly - Dosage Schedule
Table 5-20: Epkinly - Recommendations for Management of Cytokine Release Syndrome
Table 5-21: Epkinly - Recommendations for Management of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)
Table 5-22: Epkinly - Recommended Dosage Modifications for Other Adverse Reactions
Table 5-23: Talvey - Weekly Dosing Schedule
Table 5-24: Talvey - Biweekly Dosing Schedule
Table 5-25: Talvey - Recommendations for Management of CRS
Table 5-26: Talvey - Recommendations for Management of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)
Table 5-27: Talvey - Recommendations for Management of Neurologic Toxicity (excluding ICANS)
Table 5-28: Talvey - Recommended Dosage Modifications for Other Adverse Reactions
Table 5-29: Elrexfio - Dosing Schedule
Table 5-30: Elrexfio - Recommendations for Management of CRS
Table 5-31: Elrexfio - Recommended Dosage Modifications for Other Adverse Reactions
Table 5-32: Kaitani - Recommended Dose modifications
Table 5-33: Imdelltra - Recommended Concomitant Medications for Administration for Cycle 1
Table 5-34: Imdelltra - Recommended Dosage and Schedule
Table 5-35: Imdelltra - Recommendations for Restarting Therapy After Dosage Delay
Table 5-36: Imdelltra - Guidelines for Grading & Dosage Modification & Management of Cytokine Release Syndrome
Table 5-37: Imdelltra - Guidelines for Management of Neurologic Toxicity including Immune Effector Cell-Associated Neurotoxicity Syndrome
Table 5-38: Ordspono - Recommended dose
Table 5-39: Ordspono - Premedications & post-medications for patients with r/r FL or r/r DLBCL
Table 5-40: Ziihera - Dosage Modifications For Adverse Reactions
Table 5-41: Bizengri - Premedications Prior To Infusions
Table 5-42: Bizengri - Recommended Dosage Modifications & Management For Adverse Reactions
Table 5-43: Lynozyfic - Recommended Posology

02-2729-4219

+886-2-2729-4219

License/价格

多特异性抗体的全球市场:药物销售额，用量，价格，临床试验趋势(2030年)

Global Multispecific Antibodies Market, Drug Sales, Dosage, Price & Clinical Trials Insight 2030

目录

第1章下一代多重特异性抗体的简介

第2章下一代多重特异性抗体的目前临床开发与未来的商业化预测

第3章下一代多重特异性抗体临床趋势，各适应症

第4章下一代多重特异性抗体临床开发与各地区市场趋势

第5章已通过核准的多重特异性抗体- 临床概要，价格设定及用量的考察

第6章已通过核准的多重特异性抗体- 销售趋势(2020年～2025年第一季)

第7章全球重特异性抗体临床试验概要

第8章全球双特异性抗体临床试验:各企业，各适应症，各相

第9章已上市的双特异性抗体的临床性洞察:各企业，各适应症，各相

第10章全球三重特异性抗体临床试验:各企业，各适应症，各相

第11章三重特异性抗临床试验的洞察:企业，国家，适应症，各相

第12章竞争情形

Table of Contents

1. Introduction to Next Generation Multispecific Antibodies

2. Next Generation Multispecific Antibody Current Clinical Development & Future Commercialization Outlook

3. Next Generation Multispecific Antibody Clinical Trends by Indication

4. Next Generation Multispecific Antibody Clinical Development & Market Trends by Region

5. Approved Multispecific Antibodies - Clinical Overview, Pricing & Dosage Insight

6. Approved Multispecific Antibodies - Sales Insight (2020 - Q1'2025)

7. Global Multispecific Antibodies Clinical Trials Overview

8. Global Bispecific Antibodies Clinical Trials By Company, Indication & Phase

9. Marketed Bispecific Antibodies Clinical Insight By Company, Country & Indication

10. Global Trispecific Antibodies Clinical Trials Insight By Company, Country, Indication & Phase

11. Tetraspecific Antibodies Clinical Trials Insight By Company, Country, Indication & Phase